Research progress on the mechanism of circular RNA involved in platinum resistance in ovarian cancer

LIU Bin-xin; FAN Ya-dan; LYU Chun-yan; MEI Zi-man; DENG Qing-chun

doi:10.11659/jjssx.07E023007

您当前的位置：

首页 >

文章列表页 >

Research progress on the mechanism of circular RNA involved in platinum resistance in ovarian cancer

Review | 更新时间：2024-02-02

- Research progress on the mechanism of circular RNA involved in platinum resistance in ovarian cancer
- JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY Vol. 33, Issue 2, Pages: 179-182(2024)
- 作者机构：
  
  海南医学院第二附属医院妇科，海南海口 570100
- 作者简介：
- 基金信息：
- DOI：10.11659/jjssx.07E023007
  CLC： R711.75
- Published：25 February 2024，
  
  Received：03 July 2023，
扫描看全文
刘彬馨,范雅丹,吕春燕等.环状RNA参与卵巢癌铂耐药相关机制的研究进展[J].局解手术学杂志,2024,33(02):179-182.

LIU Bin-xin,FAN Ya-dan,LYU Chun-yan,et al.Research progress on the mechanism of circular RNA involved in platinum resistance in ovarian cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(02):179-182.
刘彬馨,范雅丹,吕春燕等.环状RNA参与卵巢癌铂耐药相关机制的研究进展[J].局解手术学杂志,2024,33(02):179-182. DOI： 10.11659/jjssx.07E023007.

LIU Bin-xin,FAN Ya-dan,LYU Chun-yan,et al.Research progress on the mechanism of circular RNA involved in platinum resistance in ovarian cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(02):179-182. DOI： 10.11659/jjssx.07E023007.

摘要

卵巢癌因早期诊断困难、确诊时多为晚期以及高复发率，成为致死率最高的妇科肿瘤。卵巢癌不良预后的重要原因是对铂类抗肿瘤化疗药物的耐药。环状RNA（circRNA）因其特殊的结构在细胞中较mRNA更稳定，参与调控多种肿瘤的发生、发展及化疗耐药。circRNA可作为miRNA的竞争性内源性RNA(ceRNA

）

与蛋白结合，可通过调控巨噬细胞表型极化，和作为外泌体circRNA参与调控卵巢癌铂耐药的敏感性。circRNA有望成为新的铂耐药标志物及耐药治疗新靶点。为了进一步探讨circRNA与卵巢癌铂耐药的关系，本文对近年来有关circRNA与卵巢癌铂耐药相关研究的文献进行总结。

Abstract

Ovarian cancer has become the most lethal gynecological tumor due to the difficulty in early diagnosis， the late stage when diagnosed and the high recurrence rate. Resistance to platinum-based anti-tumor chemotherapy drugs is an important reason for the poor prognosis of ovarian cancer. circular RNA （circRNA） is more stable than mRNA in cells due to its special structure， and it is involved in the regulation of the occurrence， development and chemotherapy resistance of a variety of tumors. circRNA can be used as a competing

endogenous RNA （ceRNA） of miRNA to bind to proteins，and regulates the phenotypic polarization of macrophages，it can also be used as an exosomal circRNA to regulate the sensitivity of platinum resistance in ovarian cancer. circRNA is expected to be a new marker of platinum resistance and a new target for the treatment of platinum resistance. In order to further explore the relationship between circRNA and platinum resistance in ovarian cancer， this article summarizes the recent literature related to circRNA and platinum resistance in ovarian cancer.

关键词

环状RNA卵巢癌铂耐药机制综述

Keywords

circular RNAovarian cancerplatinum resistancemechanismreview

references

Hanahan D，Weinberg RA. Hallmarks of cancer：the next generation［J］.Cell，2011，144（5）：646-674.doi：10.1016/j.cell.2011. 02.013http://dx.doi.org/10.1016/j.cell.2011.02.013.

Torre LA，Trabert B，Desantis CE，et al. Ovarian cancer statistics，2018［J］. CA Cancer J Clin，2018，68（4）：284-296.doi：10.3322/caac. 21456http://dx.doi.org/10.3322/caac.21456.

Sung H，Ferlay J，Siegel RL，et al. Global Cancer Statistics 2020：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］. CA Cancer J Clin，2021，71（3）：209-249.doi：10.3322/caac.21660http://dx.doi.org/10.3322/caac.21660.

张国楠，向阳，王登凤，等. 穿刺活检与腹水细胞学检查用于晚期卵巢癌新辅助化疗前诊断的中国专家共识（2022年版）［J］. 中国实用妇科与产科杂志，2022，38（9）：912-919.doi：10.19538/j.fk2022090111http://dx.doi.org/10.19538/j.fk2022090111.

周琦，吴小华，刘继红，等.中国卵巢上皮性癌维持治疗专家共识（2020）［J］.中国实用妇科与产科杂志，2020，36（3）：234-238.doi：10.19538/j.fk2020030113http://dx.doi.org/10.19538/j.fk2020030113.

Jiang X，Tang H，Chen T. Epidemiology of gynecologic cancers in China［J］. J Gynecol Oncol，2018，29（1）：e7.doi：10.3802/jgo. 2018.29.e7http://dx.doi.org/10.3802/jgo.2018.29.e7.

Damia G，Broggini M. Platinum resistance in ovarian cancer：role of DNA repair［J］. Cancers （Basel），2019，11（1）：119.doi：10.3390/cancers11010119http://dx.doi.org/10.3390/cancers11010119.

Morand S，Devanaboyina M，Staats H，et al. Ovarian cancer immunotherapy and personalized medicine［J］. Int J Mol Sci，2021，22（12）：6535.doi：10.3390/ijms22126532http://dx.doi.org/10.3390/ijms22126532.

Wu H，Zhao X，Wang J，et al. Circular RNA CDR1 as alleviates cisplatin-based chemoresistance by suppressing miR-1299 in ovarian cancer［J］. Front Genet，2021，12：815448.doi：10.3389/fgene. 2021.815448http://dx.doi.org/10.3389/fgene.2021.815448.

Gadducci A，Cosio S. Neoadjuvant chemotherapy in locally advanced cervical cancer：review of the literature and perspectives of clinical research［J］. Anticancer Res，2020，40（9）：4819-4828.doi：10.21873/anticanres.14485http://dx.doi.org/10.21873/anticanres.14485.

Albany C，Fazal Z，Singh R，et al. A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer［J］. Cancer Med，2021，10（1）：156-163.doi：10.1002/cam4.3583http://dx.doi.org/10.1002/cam4.3583.

Zugazagoitia J，Paz-Ares L. Extensive-stage small-cell lung cancer：first-line and second-line treatment options［J］. J Clin Oncol，2022，40（6）：671-680.doi：10.1200/jco.21.01881http://dx.doi.org/10.1200/jco.21.01881.

Powles T，Bellmunt J，Comperat E，et al. Bladder cancer：ESMO Clinical Practice Guideline for diagnosis，treatment and follow-up［J］. Ann Oncol，2022，33（3）：244-258.doi：10.1016/j.annonc. 2021.11.012http://dx.doi.org/10.1016/j.annonc.2021.11.012.

Mcquade RM，Stojanovska V，Bornstein JC，et al. Colorectal cancer chemotherapy：the evolution of treatment and new approaches［J］. Curr Med Chem，2017，24（15）：1537-1557.doi：10.2174/092986 7324666170111152436http://dx.doi.org/10.2174/0929867324666170111152436.

Geng Y，Jiang J，Wu C. Function and clinical significance of circRNAs in solid tumors［J］. J Hematol Oncol，2018，11（1）：98.doi：10.1186/s13045-018-0643-zhttp://dx.doi.org/10.1186/s13045-018-0643-z.

Jeck WR，Sorrentino JA，Wang K，et al. Circular RNAs are abundant，conserved，and associated with ALU repeats［J］. Rna，2013，19（2）：141-157.doi：10.1261/rna.035667.112http://dx.doi.org/10.1261/rna.035667.112.

Schwanhäusser B，Busse D，Li N，et al. Global quantification of mammalian gene expression control［J］. Nature，2011，473（7347）：337-342.doi：10.1038/nature10098http://dx.doi.org/10.1038/nature10098.

Huang A，Zheng H，Wu Z，et al. Circular RNA-protein interactions：functions，mechanisms，and identification［J］. Theranostics，2020，10（8）：3503-3517.doi：10.7150/thno.42174http://dx.doi.org/10.7150/thno.42174.

Wang H，Zhang X，Qiao L，et al. CircRNA circ_0000554 promotes ovarian cancer invasion and proliferation by regulating miR-567［J］. Environ Sci Pollut Res Int，2022，29（13）：19072-19080.doi：10.1007/s11356-021-13710-2http://dx.doi.org/10.1007/s11356-021-13710-2.

Zhao Y，Hu Y，Shen Q，et al. CircRNA_MYLK promotes malignant progression of ovarian cancer through regulating microRNA-652［J］. Eur Rev Med Pharmacol Sci，2020，24（10）：5281-5291.doi：10.26355/eurrev_202005_21310http://dx.doi.org/10.26355/eurrev_202005_21310.

Pei C，Wang H，Shi C，et al. CircRNA hsa_circ_0013958 may

contribute to the development of ovarian cancer by affecting epithelial-mesenchymal transition and apoptotic signaling pathways［J］. J Clin Lab Anal，2020，34（7）：e23292.doi：10.1002/jcla.23292http://dx.doi.org/10.1002/jcla.23292.

Wang J，Li Y，Zhou J H，et al. CircATRNL1 activates Smad4 signaling to inhibit angiogenesis and ovarian cancer metastasis via miR-378［J］. Mol Oncol，2021，15（4）：1217-1233.doi：10.1002/1878-0261.12893http://dx.doi.org/10.1002/1878-0261.12893.

Wu Y，Xu M，Feng Z，et al. AUF1-induced circular RNA hsa_circ_0010467 promotes platinum resistance of ovarian cancer through miR-637/LIF/STAT3 axis［J］. Cell Mol Life Sci，2023，80（9）：256.doi：10.1007/s00018-023-04906-5http://dx.doi.org/10.1007/s00018-023-04906-5.

Liu J，Wang H，Xiao S，et al. Circ_0000231 promotes paclitaxel resistance in ovarian cancer by regulating miR-140/RAP1B［J］. Am J Cancer Res，2023，13（3）：872-885.

Huang C，Qin L，Chen S，et al. CircSETDB1 contributes to paclitaxel resistance of ovarian cancer cells by sponging miR-508-3p and regulating ABCC1 expression［J］. Anticancer Drugs，2023，34（3）：395-404.doi：10.1097/cad.0000000000001465http://dx.doi.org/10.1097/cad.0000000000001465.

Dai C，Dai SY，Gao Y，et al. Circ_0078607 increases platinum drug sensitivity via miR-196b-5p/GAS7 axis in ovarian cancer［J］. Epigenetics，2023，18（1）：2175565.doi：10.1080/15592294. 2023.2175565http://dx.doi.org/10.1080/15592294.2023.2175565.

Hansen TB，Jensen TI，Clausen BH，et al. Natural RNA circles function as efficient microRNA sponges［J］. Nature，2013，495（7441）：384-388.doi：10.1038/nature11993http://dx.doi.org/10.1038/nature11993.

Zhao Z，Ji M，Wang Q，et al. Circular RNA Cdr1as Upregulates SCAI to Suppress cisplatin resistance in ovarian cancer via miR-1270

suppression［J］. Mol Ther Nucleic Acids，2019，18：24-33.doi：10.1016/j.omtn.2019.07.012http://dx.doi.org/10.1016/j.omtn.2019.07.012.

Feng X，Bai X，Ni J，et al.CHTOP in chemoresistant epithelial

ovarian cancer：a novel and potential therapeutic target［J］.Front

Oncol，2019，9：557.doi：10.3389/fonc.2019.00557http://dx.doi.org/10.3389/fonc.2019.00557.

Cao Y，Xie X，Li M，et al. CircHIPK2 contributes to DDP resistance and malignant behaviors of DDP-resistant ovarian cancer cells both in vitro and in vivo through circHIPK2/miR-338-3p/CHTOP ceRNA pathway［J］. Onco Targets Ther，2021，14：3151-3165.doi：10.2147/ott.S291823http://dx.doi.org/10.2147/ott.S291823.

Liu X，Yin Z，Wu Y，et al. Circular RNA lysophosphatidic acid

receptor 3 （circ-LPAR3） enhances the cisplatin resistance of ovarian cancer［J］. Bioengineered，2022，13（2）：3739-3750.doi：10.1080/21655979.2022.2029109http://dx.doi.org/10.1080/21655979.2022.2029109.

Qin K，Zhang F，Wang H，et al. circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis［J］. BMB Rep，2023，56（2）：184-189.doi：10.5483/BMBRep.2022-0175http://dx.doi.org/10.5483/BMBRep.2022-0175.

Jiang MP，Xu WX，Hou JC，et al. The emerging role of the interactions between circular RNAs and RNA-binding proteins in common human cancers［J］. J Cancer，2021，12（17）：5206-5219.doi：10.7150/jca.58182http://dx.doi.org/10.7150/jca.58182.

Li ZH，Zheng R，Chen JT，et al.The role of copper transporter ATP7A in platinum-resistance of esophageal squamous cell cancer （ESCC）［J］.J Cancer，2016，7（14）：2085-2092.doi：10.7150/jca.16117http://dx.doi.org/10.7150/jca.16117.

Li YQ，Yin JY，Liu ZQ，et al. Copper efflux transporters ATP7A and ATP7B：Novel biomarkers for platinum drug resistance and targets for therapy［J］. IUBMB Life，2018，70（3）：183-191.doi：10.1002/iub.1722http://dx.doi.org/10.1002/iub.1722.

Fu L，Zhang D，Yi N，et al. Circular RNA circPBX3 promotes

cisplatin resistance of ovarian cancer cells via interacting with IGF2BP2 to stabilize ATP7A mRNA expression［J］. Hum Cell，2022，35（5）：1560-1576.doi：10.1007/s13577-022-00748-8http://dx.doi.org/10.1007/s13577-022-00748-8.

林轩儒. IL-32及其诱导的细胞因子在多发性骨髓瘤发生发展中的作用及机制研究［D］.杭州：浙江大学，2018.

陈进宝.蟾毒灵调节M2型巨噬细胞极化逆转结肠癌耐药的机制研究［D］.上海：上海中医药大学，2020.

Qin J，Zhang X，Tan B，et al. Blocking P2X7-mediated macrophage polarization overcomes treatment resistance in lung cancer［J］. Cancer Immunol Res，2020，8（11）：1426-1439.doi：10.1158/2326-6066.Cir-20-0123http://dx.doi.org/10.1158/2326-6066.Cir-20-0123.

贾琳琳，陈进宝，池华博文，等. 结肠癌细胞调节M2型巨噬细胞极化促进化疗耐药的研究［J］. 中国临床药理学杂志，2022，38（21）：2564-2567.doi：10.13699/j.cnki.1001-6821.2022.21.010http://dx.doi.org/10.13699/j.cnki.1001-6821.2022.21.010.

安圆圆. MiR-21调控巨噬细胞极化并增强M2型巨噬细胞对卵巢癌细胞耐药性的促进作用［D］.辽宁：中国医科大学，2020.

Li H，Luo F，Jiang X，et al.CircITGB6 promotes ovarian cancer

cisplatin resistance by resetting tumor-associated macrophage

polarization toward the M2 phenotype［J］.J Immunother Cancer，2022，10（3）：e004029. doi：10.1136/jitc-2021-004029http://dx.doi.org/10.1136/jitc-2021-004029.

邱双洋，臧雪燕，张帆，等.外泌体环状RNA在肿瘤耐药中的作用研究进展［J］.江苏大学学报（医学版），2024：1-9［2024-01-24］.doi：10.13312/j.issn.1671-7783.y230133http://dx.doi.org/10.13312/j.issn.1671-7783.y230133.

Luo Y，Gui R. Circulating exosomal circFoxp1 confers cisplatin resistance in epithelial ovarian cancer cells［J］.J Gynecol Oncol，2020，31（5）：e75.doi：10.3802/jgo.2020.31.e75http://dx.doi.org/10.3802/jgo.2020.31.e75.

王娟娟，唐小慧，唐鸣. 血清外泌体hsa_circ_0004390预测上皮性卵巢癌铂类耐药及预后的临床研究［J］.临床肿瘤学杂志，2023，28（2）：138-144.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress of inflammation-related signaling pathways in Parkinson's disease

Effect and mechanism of PTX3 on kidney injury in mice with severe acute pancreatitis

Research progress on the relationship between vaginal microecology and female reproductive tract diseases

Mechanisms and proliferation inhibitory effects of atractylenolide I on SK-OV-3 and OVCAR-3 ovarian cancer cell

Clinical significance and expression of OPN and B7-H4 in serum of patients with epithelial ovarian cancer

Related Author

XIAO Li

LIU Ke-ting

LI Jia-hua

BAI Yun

JIA Yuan-yuan

REN Zhi-qiong

SHI Qing-ming

SHUI Yu-lian

Related Institution

Anesthesiology Major， Grade 2019， Chengdu Medical College

Anesthesiology Major， Grade 2020， Chengdu Medical College

Center of Disease Control and Prevention， Western Theater Command

Department of Neurology， Chengdu Seventh People's Hospital

Department of Human Anatomy/Development and Regeneration Key Laboratory of Sichuan Province， Chengdu Medical College

⁰